RT Journal Article
SR Electronic
T1 A reference measurement of circulating ATPase inhibitory factor 1 (IF1) in humans by LC-MS/MS: comparison with conventional ELISA
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.11.20097816
DO 10.1101/2020.05.11.20097816
A1 Genoux, Annelise
A1 Duparc, Thibaut
A1 Ruidavets, Jean-Bernard
A1 Ingueneau, Cécile
A1 Najib, Souad
A1 Ferrières, Jean
A1 Perret, Bertrand
A1 Croyal, Mikaël
A1 Martinez, Laurent O.
YR 2020
UL http://medrxiv.org/content/early/2020/05/14/2020.05.11.20097816.abstract
AB ATPase inhibitory factor 1 (IF1) is a 9.5 kDa protein that binds to mitochondrial and plasma membrane ATP synthase and selectively inhibits ATP hydrolysis. Recently, IF1 was identified in systemic circulation in humans. IF1 appeared as an independent determinant of HDL-cholesterol with lower levels in coronary heart disease (CHD) patients. Moreover, IF1 was also found to negatively associate with mortality in these patients, supporting the notion that circulating IF1 could be a promising biomarker of cardiovascular disease. However, in previous studies, IF1 was quantified by a non-standardized competitive enzyme-linked immunosorbent assay (ELISA). Herein, we have validated a liquid chromatography–tandem mass spectrometry method (LC-MS/MS) enabling the accurate quantification of IF1 in human plasma. Plasma IF1 was trypsin-digested through an optimized procedure before LC-MS/MS analysis. The method was successfully validated over 4 independent experiments into the range of 100-1,500 ng/mL. Intra- and inter-assay variation coefficients had never exceeded 14.2% and accuracy ranged between 95% and 102% for the selected EAGGAFGK peptide marker. Subsequently, the results of the LC-MS/MS method were compared with those obtained using ELISA in 204 individuals from the GENES study. We found that IF1 plasma levels obtained using both techniques were strongly correlated (r =0.89, p <0.0001), while the Bland-Altman plot did not indicate any major statistically significant differences. To clinically validate LC-MS/MS, we confirmed the positive correlation between IF1 plasma levels and HDL-cholesterol (r =0.38, p <0.0001). Besides, we found lower IF1 plasma levels in CHD patients compared to controls (431±132 ng/mL and 555±173 ng/mL, respectively; p <0.0001). Hence, it can be concluded that the presented LC-MS/MS method provides a highly specific strategy for IF1 quantification in human plasma and could be proposed as a reference technique.HighlightsATPase inhibitory factor 1 (IF1) is a biomarker of coronary heart disease in humans.Thus far, IF1 plasma concentrations have been determined by non-standardized competitive ELISA.Here, we have developed and validated an LC-MS/MS assay for the accurate IF1 quantification in human plasma.Our LC-MS/MS assay is rapid and incurs reasonable costs, thus making it amenable for clinical practice.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the French National Research Agency (ANR, #ANR-16-CE18-0014-01), European Regional Development Fund (ERDF, Fonds Européen pour le Développement Régional) and “La Région Occitanie” (Project THERANOVASC n° ESR_R&S_DF-000094/2018-003303/18009464, Project HEPATOCARE n°19014226).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are available upon request